Pharmacogenetics and cancer management

Abstract

The science of one’s genetic background and its impact on disease susceptibility and drug response has come of age and firmly established its proper place in the clinic. Its impact is felt more in the treatment of cancer than any other disease area several reasons: critical time, narrow therapeutic index and overlapping toxicity window. We realize that the true potential of pharmacogenetics will be realized when we have been able to integrate other variants like insertion-deletion, copy number variation, etc., in addition to single nucleotide polymorphism for their collective influence on drug response and toxicity. Technology has rapidly evolved and has become affordable to be used in the clinic once it gets standardized and validated not only in one population but in several major world population -particularly those which are under-represented in human variant database.

Keywords

Pharmacogenetics / drug response / DNA variants / insertion-deletion / copy number variation / therapeutic efficacy / toxicity

References

[1] Hall JM,Newman B,Anderson LA,King MC.Linkage of early-onset familial breast cancer to chromosome 17q21.Science1990;250:1684-9

[2] Vogelstein B,Velculescu VE,Diaz LAJr.Cancer genome landscapes.Science2013;339:1546-58 PMCID:PMC3749880

[3] Stratton MR,Futreal PA.The cancer genome.Nature2009;458:719-24 PMCID:PMC2821689

[4] Gupta A,H.Variability of drug response: approach to minimize toxicity andmaximize efficacy.Indian Drugs2016;53:5-10

[5] Dhawan D.Pharmacogenomics and personalized medicine for cancer..In: Barh D, Dhawan D, Ganguly NK, editors. Omics for Personalized Medicine.2013;New DelhiSpringer215-35

[6] Almal S,Agarwal M,Patel S,Jun J,Padh H.Sequencing and analysis of the whole genome of Indian Gujarati male.Genomics2018;

[7] Ciccolini J,Peters GJ.Pharmacokinetics and pharmacogenetics of gemcitabineas a mainstay in adult and pediatric oncology: an EORTC PAMMperspective.Cancer Chemother Pharmacol2016;78:1-12 PMCID:PMC4921117

[8] Sistonen J,Palo JU,Padh H.Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales.Pharmacogenet Genomics2009;19:170-9

[9] Crews KR,Pui CH,Evans WE.Pharmacogenomics and individualized medicine: translating science into practice.Clin Pharmacol Ther2012;92:467-75

[10] Relling MV.Pharmacogenomics in the clinic.Nature2015;526:343-50 PMCID:PMC4711261

[11] Redon R,Fitch KR,Perry GH,Fiegler H,Carson AR,Cho EK,Freeman JL,Gratacòs M,Kalaitzopoulos D,MacDonald JR,Mei R,Nishimura K,Shen F,Tchinda J,Woodwark C,Zhang J,Zhang J,Conrad DF,Tyler-Smith C,Aburatani H,Jones KW,Hurles ME.Global variation in copy number in the human genome.Nature2006;444:444-54 PMCID:PMC2669898

[12] Almal SH.Implications of gene copy-number variation in health and diseases.J Hum Genet2012;57:6-13

[13] Robert J,Giovannetti E.On the use of pharmacogenetics in cancer treatment and clinical trials.Eur J Cancer2014;50:2532-43